TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33221195

Group type: EXPERIMENTAL
Intervention: OTL38 (0.025mg/kg) preoperatively during lung inspection
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: OTL38 (0.025mg/kg) preoperatively during tumor resection
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: OTL38 (0.025mg/kg) preoperatively during margin check
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overall benefit of IMI
Number of subjects: 92
Study: 33618395

Group type: EXPERIMENTAL
Intervention: Early stage periarticular injection
Number of subjects: 84

Group type: COMPARATOR
Intervention: Late stage periarticular injection
Number of subjects: 84
Study: 33200439

Group type: EXPERIMENTAL
Intervention: Oral health education (OHE), toothbrushes, fluoride toothpaste, and fluoride varnish on up to six occasions
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fluoride varnish placement by medical professionals
Number of subjects: 4
Study: 36360757

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (4-month daily micronutrient packets)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no micronutrient supplementation)
Number of subjects: 45
Study: 33755846

Group type: EXPERIMENTAL
Intervention: Vasopressor administration (phenylephrine and noradrenaline)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Fluid challenges
Number of subjects: 133

Group type: COMPARATOR
Intervention: Comparison of GALA values between young and old patients
Number of subjects: 133
Study: 32940745

Group type: EXPERIMENTAL
Intervention: Interdisciplinary multimodal assessment by pain medicine specialists, physiotherapists, and clinical psychologists.
Number of subjects: 3840

Group type: COMPARATOR
Intervention: Single assessment by a pain specialist (Control).
Number of subjects: 3840
Study: 32508201

Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 0
Study: 32517844

Group type: EXPERIMENTAL
Intervention: Combined online and face-to-face dietary intervention focusing on self-compassion, goal-setting and self-monitoring
Number of subjects: 14
Study: 33450422

Group type: EXPERIMENTAL
Intervention: Short-term exposure to carbon monoxide (100-ppb increment)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Short-term exposure to nitrogen dioxide (10-ppb increment)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control group (not exposed to significant levels of air pollution)
Number of subjects: 398
Study: 33746023

Group type: EXPERIMENTAL
Intervention: Ranibizumab (intravitreal anti-VEGF agents)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real-world evidence (RWE) outcomes
Number of subjects: 0
Study: 32780999

Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin 250 mg loading dose followed by continuous infusion of 2000 mg per 24 hours
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (identical saline infusion)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 35801003

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 208188

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs) and H2 blockers
Number of subjects: 208188
Study: 34836236

Group type: EXPERIMENTAL
Intervention: Peanut Protein Supplementation (PP; 75 total g/d of powder providing 30 g/d protein, >9.2 g/d essential amino acids, 315 kcal/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (non-supplement group; CTL; n = 16 females, n = 8 males)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Peanut Protein Supplementation (PP)
Number of subjects: 47
Study: 34591551

Group type: EXPERIMENTAL
Intervention: ProSAAF prevention program
Number of subjects: 346

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 346
Study: 34435469

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Febuxostat and rasburicase
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32076569

Group type: EXPERIMENTAL
Intervention: Personalized temperature‐reduced dialysate protocol (dialysate temperature set between 0.5°C and 0.9°C below the patient’s predialysis body temperature, minimum 35.5°C)
Number of subjects: 15500

Group type: COMPARATOR
Intervention: Standard‐temperature dialysate protocol (36.5°C)
Number of subjects: 15500
Study: 36181618

Group type: EXPERIMENTAL
Intervention: Distraction-based surgery
Number of subjects: 150
Study: 33368960

Group type: EXPERIMENTAL
Intervention: LY2140112 (LY) 100 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: LY2140112 (LY) 130 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: LY2140112 (LY) 5-75 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 32389013

Group type: EXPERIMENTAL
Intervention: AMI group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PAF group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison between AMI and PAF groups
Number of subjects: 20

Group type: COMPARATOR
Intervention: SAP group
Number of subjects: 20
Study: 35132458

Group type: EXPERIMENTAL
Intervention: Neu‐BoNT/A
Number of subjects: 0
Study: 34561695

Group type: EXPERIMENTAL
Intervention: Cobicistat (150 mg q24h orally)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 32164785

Group type: EXPERIMENTAL
Intervention: Palbociclib dose reduction from 125 mg to 100 mg
Number of subjects: 311

Group type: COMPARATOR
Intervention: Palbociclib (125 mg)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Palbociclib dose reduction
Number of subjects: 311
Study: 35524006

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 33273515

Group type: EXPERIMENTAL
Intervention: Scaled equipment (smaller racket and a softer ball)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Full-sized equipment
Number of subjects: 21
Study: 35272029

Group type: EXPERIMENTAL
Intervention: Corticosteroids + 5ASA (4gr/day mesalamine)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Corticosteroids + 5ASA
Number of subjects: 149
Study: 32326806

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: GLP-1RA (liraglutide)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: SGLT-2i (empagliflozin)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: GLP-1RA + SGLT-2i (combination therapy)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (Insulin)
Number of subjects: 160
Study: 35914255

Group type: EXPERIMENTAL
Intervention: Reduced dietary sodium to less than 100 mmol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33978502

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 302
Study: 32591250

Group type: EXPERIMENTAL
Intervention: Low serum iron levels
Number of subjects: 643

Group type: COMPARATOR
Intervention: Control group (high SI levels)
Number of subjects: 643
Study: 35490936

Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU) and Methylprednisolone (40 mg)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 34531021

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (no-tablet months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Statin vs Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nocebo ratio
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stopping statin vs placebo
Number of subjects: 60
Study: 33164896

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 305

Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 305
Study: 32912727

Group type: EXPERIMENTAL
Intervention: Educational module on cost-effective ordering
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (reviewed module afterward)
Number of subjects: 63
Study: 35191924

Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine 180 μg
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine 120 μg
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 380
Study: 34025637

Group type: EXPERIMENTAL
Intervention: CAR-T-allo-HSCT
Number of subjects: 105

Group type: COMPARATOR
Intervention: Chemotherapy-allo-HSCT
Number of subjects: 105
Study: 32890299

Group type: EXPERIMENTAL
Intervention: Intraoperative wound infiltration with local anesthetics, morphine sulfate, epinephrine, and nonsteroidal anti-inflammatory drugs; postoperative patient-controlled analgesia (PCA).
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intraoperative wound infiltration with multimodal drugs; postoperative patient-controlled analgesia (PCA).
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group received only PCA postoperatively.
Number of subjects: 49
Study: 33978602

Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (VE)
Number of subjects: 17
Study: 34678128

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 45 μg/kg ideal body weight/h (iNO45)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 32033612

Group type: EXPERIMENTAL
Intervention: Protective lung ventilation (VT set at 6 ml/kg of predicted body weight with individualized PEEP during dura opening)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (VT set at 8 ml/kg of predicted body weight, no PEEP or recruitment maneuvers)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Protective lung ventilation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 32935593

Group type: EXPERIMENTAL
Intervention: LUCIA 601P IOL (non-constant aberration)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: CT ASPHINA 509M IOL (spherical aberration -0.18μm)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: AMO Tecnis ZCB00 IOL (spherical aberration -0.27μm)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Higher order aberration (all groups)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Contrast sensitivity (all groups)
Number of subjects: 77

Group type: COMPARATOR
Intervention: IOL decentration (all groups)
Number of subjects: 77

Group type: COMPARATOR
Intervention: IOL tilt (all groups)
Number of subjects: 77
Study: 33034651

Group type: EXPERIMENTAL
Intervention: Decision aid 'Go to the Hospital or Stay Here?'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36327047

Group type: EXPERIMENTAL
Intervention: AB+AA (auricular acupoint bloodletting plus auricular acupressure)
Number of subjects: 74

Group type: COMPARATOR
Intervention: AA (auricular acupressure)
Number of subjects: 74
Study: 33466131

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hyaluronic acid injection
Number of subjects: 200
Study: 35324339

Group type: EXPERIMENTAL
Intervention: Regular group (0.4mg/kg/day of methylprednisolone orally for 10 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tapering group (0.4mg/kg/day of methylprednisolone orally for 7 days, followed by progressive reduction of 8 mg per week for 3 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Regular group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tapering group
Number of subjects: 35
Study: 33263202

Group type: EXPERIMENTAL
Intervention: Exact sign test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: McNemar-type test
Number of subjects: 0
Study: 35289004

Group type: EXPERIMENTAL
Intervention: Occupational therapy-based intervention
Number of subjects: 237
Study: 34565133

Group type: EXPERIMENTAL
Intervention: Combined Isotonic Contraction Group (CIC)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional Physiotherapy Group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Repeated Stretching Group
Number of subjects: 35
Study: 36377904

Group type: EXPERIMENTAL
Intervention: Surgical Cost Awareness Program (real-time cost awareness software)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 322
Study: 32111230

Group type: EXPERIMENTAL
Intervention: 4% albumin solution
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Ringer's acetate solution
Number of subjects: 1386
Study: 35023557

Group type: EXPERIMENTAL
Intervention: Sodium Benzoate (250-1500 mg/d)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sertraline (25-150 mg/d)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 34859831

Group type: EXPERIMENTAL
Intervention: Aura intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 34962665

Group type: EXPERIMENTAL
Intervention: SRP + diode laser (0.80W power, 940 nm wavelength, 0.80J/s energy level)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Only SRP group
Number of subjects: 40
Study: 32537732

Group type: EXPERIMENTAL
Intervention: Matrix rhythm therapy (MRT) combined with Bobath therapy (BT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bobath therapy (BT)
Number of subjects: 30
Study: 35509085

Group type: EXPERIMENTAL
Intervention: 300 mg oral ferrous sulfate (60 mg of elemental iron) daily for 12 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: 300 mg oral ferrous sulfate (60 mg of elemental iron) every other day for 12 weeks
Number of subjects: 52
Study: 33446152

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 82
Study: 33234798

Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectal excision with Denonvilliers' fascia preservation (Exp-group, n = 123)
Number of subjects: 253
Study: 35175934

Group type: EXPERIMENTAL
Intervention: Flow-controlled expiration (FLEX) ventilation
Number of subjects: 8
Study: 34294510

Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy
Number of subjects: 999
Study: 35332040

Group type: EXPERIMENTAL
Intervention: HN001 capsules
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: OBG cereal
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control cereal
Number of subjects: 153

Group type: COMPARATOR
Intervention: HN001 vs Placebo
Number of subjects: 153

Group type: COMPARATOR
Intervention: OBG vs Control
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 153
Study: 32526362

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 961

Group type: COMPARATOR
Intervention: Curative treatment
Number of subjects: 961

Group type: COMPARATOR
Intervention: Active UIA treatment
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Endovascular treatment or surgical treatment
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Overall management
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Hospitalization duration
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Discharge location
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Subarachnoid hemorrhage incidence
Number of subjects: 961
Study: 34994794

Group type: EXPERIMENTAL
Intervention: Therapeutic aquatic exercise
Number of subjects: 113

Group type: COMPARATOR
Intervention: Physical therapy modalities
Number of subjects: 113
Study: 32384727

Group type: EXPERIMENTAL
Intervention: Three-day bamboo forest therapy session
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bamboo forest sites (YA, YB, DJY)
Number of subjects: 120
Study: 32635877

Group type: COMPARATOR
Intervention: Closed extracorporeal membrane oxygenation circuits (wet primed) inoculated with Escherichia coli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open circuits (dry setup)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed circuits (dry setup)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open, wet-primed circuits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed, wet-primed circuits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood-primed circuits
Number of subjects: 0
Study: 35139822

Group type: EXPERIMENTAL
Intervention: C + ECD group sessions
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: T + enhanced play materials package
Number of subjects: 75

Group type: COMPARATOR
Intervention: Status quo (community-based health and nutrition program)
Number of subjects: 75
Study: 33647776

Group type: EXPERIMENTAL
Intervention: Huangqi decoction (HQD) components including astragaloside IV, cycloastragenol, glycyrrhizic acid, glycyrrhetinic acid, liquiritigenin, and isoliquiritigenin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Huangqi decoction (HQD) components including cycloastragenol, calycosin‐7‐O‐β‐D‐glucoside, formononetin, glycyrrhetinic acid, liquiritin, and isoliquiritin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Huangqi decoction (HQD) components including calycosin, liquiritigenin, isoliquiritigenin, cycloastragenol, and glycyrrhetinic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-component combination of HQD (MCHD)
Number of subjects: 0
Study: 32149887

Group type: EXPERIMENTAL
Intervention: MJ + SJ (barbell bench press plus lying barbell triceps press)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SJ + MJ (lying barbell triceps press plus barbell bench press)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MJ (barbell bench press)
Number of subjects: 43

Group type: COMPARATOR
Intervention: SJ (lying barbell triceps press)
Number of subjects: 43
Study: 36068191

Group type: EXPERIMENTAL
Intervention: Unstable group (UG) functional exercises for 8 weeks, 3 days/week, 1 hour/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Stable group (SG) functional exercises for 8 weeks, 3 days/week, 1 hour/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (CG); no training
Number of subjects: 34
Study: 33285650

Group type: EXPERIMENTAL
Intervention: hMHS‐rTMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HK‐rTMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham‐rTMS
Number of subjects: 10
Study: 33118309

Group type: EXPERIMENTAL
Intervention: Basal insulin users with continuous glucose monitoring (CGM)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Blinded CGM
Number of subjects: 173

Group type: COMPARATOR
Intervention: Real-time CGM
Number of subjects: 173
Study: 35202890

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.2 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.1 mg
Number of subjects: 225

Group type: COMPARATOR
Intervention: Laser
Number of subjects: 225
Study: 33492175

Group type: EXPERIMENTAL
Intervention: Cogstate Brief Battery (CBB) performed to the best of their ability
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cogstate Brief Battery (CBB) simulated cognitive impairment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Detection task of the CBB
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 64
Study: 34166289

Group type: EXPERIMENTAL
Intervention: Model predicting impending ICU hypoglycemia using 61 physiologic markers.
Number of subjects: 11847

Group type: EXPERIMENTAL
Intervention: External validation of the model in the Medical Information Mart for Intensive Care III dataset.
Number of subjects: 11847
Study: 34925044

Group type: EXPERIMENTAL
Intervention: Ginkgolide® treatment with IV rt‐PA
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Control group (IV rt‐PA only)
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Ginkgolide® treatment with IV rt‐PA after propensity score matching
Number of subjects: 1113
Study: 32556356

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 88
Study: 36692224

Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention
Number of subjects: 363

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 363
Study: 32948867

Group type: EXPERIMENTAL
Intervention: Whey protein (WP) hydrolysate
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Whey protein (WP) combined with low-fiber (LoFi; 10 g dietary fiber/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Maltodextrin (MD)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Whey protein (WP) and dietary fiber from wheat bran
Number of subjects: 73
Study: 32854834

Group type: EXPERIMENTAL
Intervention: MitraClip plus GDMT
Number of subjects: 614

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study: 35412478

Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses (MFCLs)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Progressive addition lenses for general purpose (GP-PALs)
Number of subjects: 11
Study: 33524320

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 192

Group type: COMPARATOR
Intervention: Sham/control
Number of subjects: 192
Study: 32418856

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) administered intraoperatively after open arthrolysis
Number of subjects: 61

Group type: COMPARATOR
Intervention: Saline administration (control group)
Number of subjects: 61
Study: 35458181

Group type: EXPERIMENTAL
Intervention: Blueberry supplementation
Number of subjects: 0
Study: 33760010

Group type: EXPERIMENTAL
Intervention: Intrawound vancomycin powder (1000 mg)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Standard infection prevention protocol without vancomycin
Number of subjects: 980
Study: 32337268

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study: 35982481

Group type: EXPERIMENTAL
Intervention: Developed algorithm for sleep/wake states using FS-760
Number of subjects: 65

Group type: COMPARATOR
Intervention: Adult algorithm applied to children's activity
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 65